-
Tytuł:
-
Detection of soluble ERBB2 in breast cancer cell lysates using a combined label-free/fluorescence platform based on Bloch surface waves.
-
Autorzy:
-
Sinibaldi A; Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 16, 00161 Rome, Italy. Electronic address: .
Sampaoli C; Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
Danz N; Fraunhofer Institute for Applied Optics and Precision Engineering IOF, Albert-Einstein-Str. 7, 07745 Jena, Germany.
Munzert P; Fraunhofer Institute for Applied Optics and Precision Engineering IOF, Albert-Einstein-Str. 7, 07745 Jena, Germany.
Sibilio L; IBI, Istituto Biochimico Italiano Giovanni Lorenzini Spa, Via Fossignano 2, 04011 Aprilia, Italy.
Sonntag F; Fraunhofer Institute for Material and Beam Technology IWS, Winterbergstr. 28, 01277 Dresden, Germany.
Occhicone A; Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 16, 00161 Rome, Italy.
Falvo E; Institute of Molecular Biology and Pathology, National Research Council, P.le Aldo Moro 5, 00185 Rome, Italy.
Tremante E; Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
Giacomini P; Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
Michelotti F; Department of Basic and Applied Science for Engineering, Sapienza University of Rome, Via A. Scarpa 16, 00161 Rome, Italy.
-
Źródło:
-
Biosensors & bioelectronics [Biosens Bioelectron] 2017 Jun 15; Vol. 92, pp. 125-130. Date of Electronic Publication: 2017 Feb 09.
-
Typ publikacji:
-
Evaluation Study; Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Oxford : Elsevier Advanced Technology
Original Publication: [Barking, Essex, England] : Elsevier Applied Science, 1989-
-
MeSH Terms:
-
Biosensing Techniques/*instrumentation
Breast/*pathology
Breast Neoplasms/*diagnosis
Receptor, ErbB-2/*analysis
Antibodies, Monoclonal/chemistry ; Biomarkers, Tumor/analysis ; Cell Line, Tumor ; Equipment Design ; Female ; Fluorescence ; Humans ; Lab-On-A-Chip Devices ; Limit of Detection
-
Contributed Indexing:
-
Keywords: 1D photonic crystals; Bloch surface waves; Breast cancer; ERBB2; Optical biosensors; SK-BR 3
-
Substance Nomenclature:
-
0 (Antibodies, Monoclonal)
0 (Biomarkers, Tumor)
EC 2.7.10.1 (ERBB2 protein, human)
EC 2.7.10.1 (Receptor, ErbB-2)
-
Entry Date(s):
-
Date Created: 20170218 Date Completed: 20170328 Latest Revision: 20191210
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.bios.2017.02.012
-
PMID:
-
28209555
-
We report on the use of one-dimensional photonic crystals to detect clinically relevant concentrations of ERBB2/neu/Her2 in cell lysates. ERBB2 is a pivotal breast cancer biomarker and targetable oncogenic driver associated with aggressive breast cancer subtypes. To quantitate soluble ERBB2, we developed an optical platform that combines label-free and fluorescence detection modes. Such platform makes use of a sandwich assay in which the one-dimensional photonic crystals sustaining Bloch surface waves are tailored with a monoclonal antibody for highly specific biological recognition (BSW biochip). In a second step, a second antibody to ERBB2 quantitatively detects the bound analyte. The strategy of the present approach takes advantage of the combination of label-free and fluorescence techniques, making bio-recognition more robust and sensitive. In the fluorescence operation mode, the platform can attain the limit of detection 0.3ng/mL (1.5pM) for ERBB2 in cell lysates. Such resolution meets the international guidelines and recommendations (15ng/mL) for diagnostic ERBB2 assays that in the future may help to more precisely assign therapies counteracting cancer cell proliferation and metastatic spread.
(Copyright © 2017 Elsevier B.V. All rights reserved.)
